Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced <i>EGFR</i>-Mutant Non–Small Cell Lung Cancer
-
- Thomas E. Stinchcombe
- Duke Cancer Institute, Durham, North Carolina
-
- Pasi A. Jänne
- Dana Farber Cancer Institute, Boston, Massachusetts
-
- Xiaofei Wang
- Alliance Data and Statistical Center, Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina
-
- Erin M. Bertino
- The Ohio State University Comprehensive Cancer Center, Columbus
-
- Jared Weiss
- University of North Carolina Lineberger Cancer Center at Chapel Hill
-
- Lyudmila Bazhenova
- Moores Cancer Center, University of California, San Diego
-
- Lin Gu
- Alliance Data and Statistical Center, Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina
-
- Christie Lau
- Dana Farber Cancer Institute, Boston, Massachusetts
-
- Cloud Paweletz
- Dana Farber Cancer Institute, Boston, Massachusetts
-
- Anthony Jaslowski
- Saint Vincent Hospital Cancer Center, Green Bay, Wisconsin
-
- Gregory J. Gerstner
- Illinois Cancer Care-Peoria, Peoria, Illinois
-
- Maria Q. Baggstrom
- Division of Medical Oncology, Washington University School of Medicine in St Louis, Missouri
-
- Stephen Graziano
- Division of Hematology and Oncology, State University of New York Upstate Medical University, Syracuse
-
- James Bearden
- Spartanburg Regional Health, Spartanburg, South Carolina
-
- Everett E. Vokes
- Biological Sciences Division, University of Chicago Medicine, Chicago, Illinois
書誌事項
- タイトル別名
-
- A Phase 2 Randomized Clinical Trial
収録刊行物
-
- JAMA Oncology
-
JAMA Oncology 5 (10), 1448-, 2019-10-01
American Medical Association (AMA)